Articles From: Lifshitz & Miller Law Firm Announces Investigation of American Realty Capital Properties Inc., Covance Inc., Elecsys Corporation, ESB Financial Corporation, Hudson Valley Holding Corp., Monarch Community Bancorp, Inc., and Penford Corporation to Lighting Science Receives $13.0 Million Equity Investment to Fund Growth


2014/11/26
Iconic Seattle chef's onboard dish to begin flying Dec.
Sign-up for Lift Your Palate: Alaska Airlines, Tom Douglas Partner to Bring Signature Dishes to the Skies investment picks
2014/10/31
Out-of-this-World Trip Made Possible Through a First of its Kind Partnership Between Paramount Pictures, Fandango, Motherboard and XCOR Aerospace LOS ANGELES , Oct.
Sign-up for LIFTING OFF TODAY, FANDANGO'S "INTERSTELLAR" TICKET-BUYERS CAN ENTER FOR A CHANCE TO WIN A TRIP TO THE FRONTIER OF SPACE ON XCOR'S LYNX SPACECRAFT investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for Revolade™ (eltrombopag), seeking an additional indication for the treatment of adult patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST). SAA is a rare disorder in which the bone marrow fails to make enough new blood cells.
Sign-up for Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade™ (eltrombopag) investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration for eltrombopag (Promacta), seeking an additional indication in pediatric patients six years old and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Sign-up for Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta® investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Melinta Therapeutics reported positive top-line results from the first of two Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to evaluate delafloxacin, an investigational fluoroquinolone, compared with vancomycin + aztreonam for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Delafloxacin met the study’s primary objective endpoint of a reduction in the measurement of lesion erythema at the primary infection site at 48- to- 72 hours, the endpoint required by the U.S. Food and Drug Administration (FDA). Delafloxacin also was comparable to vancomycin in the study’s secondary endpoints, including investigator assessment of signs and symptoms of infection at the follow-up visit, a metric required by the European Medicines Agency (EMA).
Sign-up for Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results for Captisol-enabled™ Delafloxacin IV investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Pfizer has received EU marketing authorization for DUAVIVE® (conjugated estrogens/bazedoxifene (BZA/CE)) from the European Commission.
Sign-up for Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE® (Conjugated Estrogens/Bazedoxifene) for Treatment of Estrogen Deficiency Symptoms in Postmenopausal Women with a Uterus investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Retrophin, Inc. (NASDAQ:RTRX) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for Sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS). “Sparsentan has the potential to be a significant medicine, and could transform the treatment of FSGS,” said John Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals.
Sign-up for Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner Spectrum Pharmaceuticals (NASDAQ: SPPI) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Captisol-enabled™ Melphalan (CE-Melphalan) HCl for injection (propylene glycol-free) for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
Sign-up for Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled™ Melphalan investment picks
At an Analyst Day event held earlier today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the financial leverage in its business model, revenue growth opportunities and its portfolio of partnered assets and unpartnered development programs, as well as its Captisol formulation technology and its financial outlook through 2017.
Sign-up for Ligand Provides Highlights from Today’s Analyst Day Event investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2014, and provided an operating forecast and program updates.
Sign-up for Ligand Reports Third Quarter 2014 Financial Results investment picks
2015/1/14
NEW AT LIGHT FOR THEIR LAS VEGAS RESIDENCY ARE DISCLOSURE, DJ MUSTARD, FAT BOY SLIM, MACKLEMORE & RYAN LEWIS AND will.i.am ALESSO, A-TRAK, AXWELL, BAAUER, CARL COX AND INGROSSO RETURN WILL SOON UNVEIL NEW ARTISTIC DIRECTION FOR 2015 LAS VEGAS , Jan.
Sign-up for LIGHT Nightclub At Mandalay Bay Resort And Casino In Las Vegas Announces Talent Roster For 2015 investment picks
MCLEAN, Va., Nov.
Sign-up for Lightbridge Announces $5.04 Million Registered Direct Offering investment picks
2014/11/19
Live Conference Call and Webcast Scheduled at 11 a.m. ET Thursday, November 20 at: http://www.media-server.com/m/p/3x3dhdmr MCLEAN, Va., Nov.
Sign-up for Lightbridge Announces 2014 Third Quarter Business Update investment picks
2014/11/12
Live Conference Call and Webcast Scheduled at 11 a.m. ET Thursday, November 20, at : http://www.media-server.com/m/p/3x3dhdmr MCLEAN, Va., Nov.
Sign-up for Lightbridge to Host November 20 Conference Call and Webcast on 2014 Third Quarter Business Update and Financial Results investment picks
Cloud-Based Content Management System Enables Growth for Designers and Design Agencies OKLAHOMA CITY , Dec.
Sign-up for LightCMS Super Charges Steadfast Creative's Growth From One-Person Startup To A Thriving Digital Agency investment picks
Lighting Science Group Corporation (OTCQB: LSCG) is pleased to announce the launch of the new Vintage™ Filament Series of LED lamps.
Sign-up for Lighting Science Group Unveils Much Anticipated Vintage Filament Series LED Lamps investment picks
2014/11/19
Lighting Science Group Corporation announced that it has received $13.0 million in preferred stock financing from Serengeti Asset Management.
Sign-up for Lighting Science Receives $13.0 Million Equity Investment to Fund Growth investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Lifshitz & Miller Law Firm Announces Investigation of American Realty Capital Properties Inc., Covance Inc., Elecsys Corporation, ESB Financial Corporation, Hudson Valley Holding Corp., Monarch Community Bancorp, Inc., and Penford Corporation to Lighting Science Receives $13.0 Million Equity Investment to Fund Growth
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent